Patent · US Active

CD73 blockade

US11958907B2 · kind B2 · utility

1Cited by

3References

21Claims

0Family size

Assignee

INNATE PHARMA · FR

Inventors

Ivan Perrot · Cassis, FR
Carine Paturel · Tassin-la-Demi-Lune, FR
Laurent Gauthier · Toulouse, FR

Key dates

Filing date	Sep 2, 2020
Grant date	Apr 16, 2024
Priority date	—
Expiry date	Nov 28, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.